ArticleCell transplantation
Total marrow irradiation-based conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A multicenter real-world study.
Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is very limited large-scale real-world data on the use of total marrow irradiation (TMI) as conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective of this study was to evaluate the real-world feasibility, efficacy, and safety of TMI-based conditioning in a large multicenter cohort. We retrospectively included consecutive patients undergoing allo-HSCT with TMI-based conditioning across four Chinese centers (2017-2024). The primary endpoint was overall survival (OS); secondary endpoints included disease-free survival (DFS), graft-versus-host disease-free/relapse-free survival (GRFS), nonrelapse mortality (NRM), graft-versus-host disease (GVHD), and safety. Among 205 patients, acute lymphoblastic leukemia (ALL) was the predominant diagnosis (81.5%). With a median follow-up of 19.3 months among survivors, 2-year OS, DFS, and GRFS were 71.7%, 60.0%, and 37.8%, respectively. One-year cumulative incidences of relapse and NRM were 20.2% and 13.8%. Day-100 grade II-IV acute GVHD occurred in 32.9%, and 1-year moderate-to-severe chronic GVHD in 19.1%. In multivariable analyses, acute myeloid leukemia (AML) diagnosis, haploidentical donor, and Eastern Cooperative Oncology Group (ECOG) performance status >1 were associated with inferior outcomes. Exploratory dose-stratified analyses were performed. Severe toxicities within 100 days were infrequent, predominantly infections (21.46%). In this large multicenter cohort, TMI-based conditioning demonstrated real-world feasibility with encouraging survival and manageable safety outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.